A Phase II Study of Etoposide, Oxaliplatin and Capecitabine in Patients With Advanced HCC
Open phase II study.
Response rate for the combination of etoposide, oxaliplatin and capecitabine given every 3
weeks on an outpatient basis.
Secondary endpoint are safety, time to progression and survival
Etoposide are administered intravenously 100 mg/m2 on day 1 and orally 200 mg/m2 on days 2
Capecitabine (Xeloda) are administered 1000 mg/m2 twice daily with 12 hours interval for two
weeks and one week off
Oxaliplatin are administered intravenously 100 mg/m2 on day 1 in each cycle as a 2 hours
One cycle is 3 weeks.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Ulrik Lassen, MD., PH.D.
Rigshospitalet, Dept. of Oncology
Denmark: Danish Medicines Agency